Australia - angielski - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 300 g/l - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate solution injection for intravenous infusion is indicated for the treatment of vitamin c deficiency when oral treatment is not feasible.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - dopamine hydrochloride, quantity: 200 mg - injection, concentrated - excipient ingredients: sodium chloride; potassium metabisulfite; water for injections; hydrochloric acid; sodium hydroxide - for the correction of haemodynamic imbalance present in: acute hypotension or shock associated with myocardial infarction, endotoxic septicaemia, trauma and renal failure. as an adjunct after open heart surgery, where there is persistent hypotension after correction of hypovolaemia. in chronic cardiac decompensation as in congestive failure.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 100 mg/ml; disodium edetate, quantity: 60 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide - 1. disodium edetate is particularly effective in treating lead accumulation and lead poisoning. this is especially so where there is a concomitant hypercalcaemic problem (refer "indications (2)"). however it must be noted that disodium edetate is equally effective with calcium disodium edetate in removing heavy metals, even in the absence of hypercalcaemia. for patients with elevated serum calcium or hypermobility of their body pools of calcium where there may be transiently or prolonged raised serum calcium (see "indications (2)"), the edta of choice for removing heavy metals may be disodium edetate. there are no recognised safe limits for lead intoxication. lead poisoning may occur by ingestion or inhalation of lead dust or fumes. poisoning is manifested by a metallic taste, anorexia, irritability, apathy, abdominal colic, vomiting, diarrhoea, constipation, headache, leg cramps, black stools, oliguria, stupor, convulsions, palsies and coma. chronic lead poisoning causes variable involvement of the central n

Kanada - angielski - Health Canada

ratiopharm inc division of teva canada limited - orciprenaline sulfate - syrup - 2mg - orciprenaline sulfate 2mg - selective beta 2-adrenergic agonists

Malta - angielski - Medicines Authority

monico spa via ponte di pietra 7, 30173, venice, italy - isoprenaline hydrochloride - solution for injection - isoprenaline hydrochloride 0.2 mg/ml - cardiac therapy

Malta - angielski - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - isoprenaline hydrochloride - solution for injection - isoprenaline hydrochloride 0.2 mg/ml - cardiac therapy

Australia - angielski - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - esmolol hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium acetate trihydrate; glacial acetic acid - supraventricular tachycardia - for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol is also indicated in non-compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. esmolol is not intended for use in chronic settings where transfer to another agent is anticipated, or for treatment periods greater than 24 hours duration.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - esmolol hydrochloride, quantity: 2500 mg - injection, powder for - excipient ingredients: - supraventricular tachycardia,brevibloc (esmolol hcl) is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. brevibloc is also indicated in non compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. brevibloc is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

herbal supplies pty ltd - eleutherococcus senticosus -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 0.6 mg/ml (equivalent: salbutamol, qty 0.5 mg/ml) - injection, solution - excipient ingredients: sodium chloride; sulfuric acid; water for injections - indications as at 3rd december 2002: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm.